Search - Inserm - Institut national de la santé et de la recherche médicale Access content directly

Filter your results

24 Results
authFullName_s : Michel Jourdan
Image document

Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.

Michel Jourdan , Jérôme Moreaux , John De Vos , Dirk Hose , Karène Mahtouk , et al.
British Journal of Haematology, 2007, 138 (2), pp.160-8. ⟨10.1111/j.1365-2141.2007.06629.x⟩
Journal articles inserm-00160647v1
Image document

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Anne Catherine Sprynski , Dirk Hose , Laurent Caillot , Thierry Rème , John D. Shaughnessy Jr , et al.
Blood, 2009, 113 (19), pp.4614-4626. ⟨10.1182/blood-2008-07-170464⟩
Journal articles inserm-00367812v1
Image document

Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.

Karène Mahtouk , Friedrich W. Cremer , Thierry Rème , Michel Jourdan , Marion Baudard , et al.
Oncogene, 2006, 25 (54), pp.7180-91. ⟨10.1038/sj.onc.1209699⟩
Journal articles inserm-00128880v1
Image document

Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.

Michel Jourdan , Karin Tarte , Eric Legouffe , Jean Brochier , Jean-François Rossi , et al.
European Cytokine Network, 1999, 10 (1), pp.65-70
Journal articles inserm-00142273v1
Image document

Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.

Michel Jourdan , Karène Mahtouk , Jean-Luc Veyrune , Guilhem Couderc , Geneviève Fiol , et al.
European Cytokine Network, 2005, 16 (1), pp.57-64
Journal articles inserm-00130868v1
Image document

Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

Karène Mahtouk , Dirk Hose , Pierre Raynaud , Michael Hundemer , Michel Jourdan , et al.
Blood, 2007, 109 (11), pp.4914-23. ⟨10.1182/blood-2006-08-043232⟩
Journal articles inserm-00136105v1
Image document

Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Karène Mahtouk , Jérôme Moreaux , Dirk Hose , Thierry Rème , Tobias Meissner , et al.
BMC Cancer, 2010, 10 (1), pp.198. ⟨10.1186/1471-2407-10-198⟩
Journal articles inserm-00668220v1

Interleukin-6 as a Therapeutic Target

Jean-François Rossi , Zhao-Yang Lu , Michel Jourdan , Bernard Klein
Clinical Cancer Research, 2015, 21 (6), pp.1248-1257. ⟨10.1158/1078-0432.CCR-14-2291⟩
Journal articles hal-02137928v1
Image document

Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.

Michel Jourdan , Thierry Rème , Harmut Goldschmidt , Geneviève Fiol , Véronique Pantesco , et al.
British Journal of Haematology, 2009, 145, pp.45-58. ⟨10.1111/j.1365-2141.2008.07562.x⟩
Journal articles inserm-00358309v1
Image document

The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.

Karin Tarte , Michel Jourdan , Jean-Luc Veyrune , Ingolf Berberich , Geneviève Fiol , et al.
British Journal of Haematology, 2004, 125 (3), pp.373-82. ⟨10.1111/j.1365-2141.2004.04908.x⟩
Journal articles inserm-00368387v1
Image document

Microarray-based understanding of normal and malignant plasma cells.

John de Vos , Dirk Hose , Thierry Rème , Karin Tarte , Jérôme Moreaux , et al.
Immunological Reviews, 2006, 210, pp.86-104. ⟨10.1111/j.0105-2896.2006.00362.x⟩
Journal articles inserm-00149827v1
Image document

An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization.

Michel Jourdan , Anouk Caraux , John de Vos , Geneviève Fiol , Marion Larroque , et al.
Blood, 2009, 114 (25), pp.5173-81. ⟨10.1182/blood-2009-07-235960⟩
Journal articles inserm-00446133v1
Image document

Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.

Karène Mahtouk , Dirk Hose , Thierry Rème , John de Vos , Michel Jourdan , et al.
Oncogene, 2005, 24 (21), pp.3512-24. ⟨10.1038/sj.onc.1208536⟩
Journal articles inserm-00130206v1
Image document

An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis.

Karène Mahtouk , Michel Jourdan , John de Vos , Catherine Hertogh , Geneviève Fiol , et al.
Blood, 2004, 103 (5), pp.1829-37. ⟨10.1182/blood-2003-05-1510⟩
Journal articles inserm-00130207v1
Image document

Survival and proliferation factors of normal and malignant plasma cells.

Bernard Klein , Karin Tarte , Michel Jourdan , Karene Mathouk , Jérôme Moreaux , et al.
International Journal of Hematology, 2003, 78 (2), pp.106-13
Journal articles inserm-00130900v1
Image document

APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.

Jérôme Moreaux , Anne-Catherine Sprynski , Stacey R. Dillon , Karène Mahtouk , Michel Jourdan , et al.
European Journal of Haematology, 2009, 83 (2), pp.119-29. ⟨10.1111/j.1600-0609.2009.01262.x⟩
Journal articles inserm-00397249v1
Image document

Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.

Karène Mahtouk , Dirk Hose , John de Vos , Jérôme Moreaux , Michel Jourdan , et al.
Clinical Cancer Research, 2007, 13 (24), pp.7289-95. ⟨10.1158/1078-0432.CCR-07-1758⟩
Journal articles inserm-00270566v1
Image document

A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.

Michel Jourdan , Jean-Luc Veyrune , John De Vos , Nicole Redal , Guilhem Couderc , et al.
Oncogene, 2003, 22 (19), pp.2950-9. ⟨10.1038/sj.onc.1206423⟩
Journal articles inserm-00130855v1
Image document

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Jérôme Moreaux , Bernard Klein , Régis Bataille , Géraldine Descamps , Sophie Maïga , et al.
Haematologica, 2011, 96 (4), pp.574-82. ⟨10.3324/haematol.2010.033456⟩
Journal articles inserm-00550232v1
Image document

TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.

Jérôme Moreaux , Dirk Hose , Michel Jourdan , Thierry Rème , Michael Hundemer , et al.
Haematologica, 2007, 92 (6), pp.803-11
Journal articles inserm-00162002v1
Image document

GenomicScape: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells

Alboukadel Kassambara , Thierry Rème , Michel Jourdan , Thierry Fest , Dirk Hose , et al.
PLoS Computational Biology, 2015, 11 (1), pp.e1004077. ⟨10.1371/journal.pcbi.1004077⟩
Journal articles hal-01112225v1
Image document

Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

Anne Catherine Sprynski , Dirk Hose , Alboukadel Kassambara , Laure Vincent , Michel Jourdan , et al.
Leukemia, 2010, 24 (11), pp.1940-50. ⟨10.1038/leu.2010.192⟩
Journal articles inserm-00528166v1
Image document

Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.

Michel Jourdan , John de Vos , Nadir Mechti , Bernard Klein
Cell Death and Differentiation, 2000, 7 (12), pp.1244-52. ⟨10.1038/sj.cdd.4400758⟩
Journal articles inserm-00130981v1
Image document

Characterization of human FCRL4-positive B cells

Michel Jourdan , Nicolas Robert , Maïlys Cren , Coraline Thibaut , Christophe Duperray , et al.
PLoS ONE, 2017, 12 (6), pp.e0179793. ⟨10.1371/journal.pone.0179793⟩
Journal articles hal-01560458v1